Pooled analyses of randomized controlled trials onpyrotinib plus capecitabine and a rethink of the first-line options for HER2-positive relapsed or metastatic breast cancer

作     者：Xiuwen Guan Fei Ma Binghe Xu 

作者机构：Department of Medical OncologyNational Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina Department of Medical Oncology and Clinical Trial CenterNational Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina 

出 版 物：《Cancer Innovation》 (肿瘤创新（英文）)

年 卷 期：2022年第1卷第2期

页      面：119-123页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：National Nature Science Foundation of China,Grant/Award Number:8210114934 CAMS Innovation Fund for Medical Sciences,Grant/Award Numbers:CIFMS,2021-I2M-1-014 

主　　题：breast cancer tyrosine kinase inhibitor HER2-targeted therapy 

摘      要：Human epidermal growth factor receptor 2(HER2)-positive breast cancer,which accounts for 15%-20% of breast cancers,is associated with aggressive tumor behavior and conferred a poor outcome before the era of HER2-targeted *** advent of anti-HER2 antibodies(trastuzumab and pertuzumab),antibody-drug conjugates(ADCs,ado-trastuzumab emtansine and trastuzumab deruxtecan),and HER2‐tyrosine kinase inhibitors(TKIs,neratinib and lapatinib),have dramatically improved the treatment response and survival of this aggressive subtype.